Market Overview

Anti-Neprilysin Drug Market is projected to achieve a value of USD 1,263 Million in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 2,183 Million by 2033 with a CAGR of 4.9% during the forecast period 2023-2033.

Anti-Neprilysin drug are mostly used in the treatment of acute heart failure. Hart failure is chronic progressive condition of heart muscles is unable to pump enough amount of blood to the body parts. The most widely used Anti-Neprilysin drug medication is Sacubitril/valsartan, available under the brand name Entrest. It is composed of the neprilysin inhibiting agent sacubitril and the angiotensin receptor blocking drug valsartan.

The increasing the prevalence of diseases like Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others drive the market growth in the forecasted period. Additionally, rising the incidences of heart diseases, increasing the government support for awareness campaign, robust research and development investment will fuel to drive the Anti-Neprilysin drug market.

For instance, as on June 2, 2022, Cipla Inc., an India-based biopharmaceutical and medical company, announced the commercial operation of additional capacity of captive renewable energy power plants in Maharashtra and Karnataka, India. This initiative is designed to fulfill the company's green energy demands for their manufacturing facilities located in Kurkumbh and Patalganga, both situated in India, as well as their research and development center in Maharashtra. It will effectively replace approximately 70% of the total energy consumption for these units with eco-friendly, renewable energy sources.

COVID 19 pandemic shown the negative Impacts on the growth of Anti-Neprilysin drug market. During the COVID-19 pandemic worldwide lockdown was imposed. As a COVID patient increased governments banned all transportation, restriction on vising of regular follow-up patients in hospital, it will impact on the patient treatment having chronic diseases and delay in elective or non-elective surgeries.

For instance, according to an article published in July 2022, in PubMed, a free search engine for biological databases and medical reports, it was reported that approximately 2.3 million cancer surgeries were delayed on a global scale during the early stages of the COVID-19 pandemic. These delays in cancer surgeries were primarily a consequence of the strain COVID-19 imposed on hospital resources and the heightened concerns regarding the increased risk of pulmonary complications linked to COVID-19 among cancer patients. 

Market Scope

Report Attributes	Description
Market Size in 2022	USD 1,034 Million
Market Forecast in 2033	USD 2,183 Million
CAGR % 2023-2033	4.9%
Base Year	2022
Historic Data	2016-2022
Forecast Period	2023-2033
Report USP	Consumption, company share, company heatmap, company production capacity, growth factors and more
Segments Covered	by Drug Type, by Indication, by Distribution Channel
Growth Drivers	Increasing Prevalence of Heart Failure Anti-neprilysin drugs are often used in combination with angiotensin receptor blockers (ARBs) to enhance their effectiveness. Ongoing research and development in the pharmaceutical industry have led to the discovery and development of new anti-neprilysin drugs, expanding the available options.
Regional Scope	North America, Europe, APAC, South America and Middle East and Africa
Country Scope	U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria
Key Companies	Novartis AG, BIOPROJET, Pharmaleads SA,  Cipla Inc, Oceanic Pharmachem Pvt. Ltd., Theravance Biopharm

 Market Dynamics

The growth of the Anti-Neprilysin drug market is significantly driven by increasing prevalence of acute heart failure, an upsurge in government support and surveillance at both national and global levels. Furthermore, substantial investments by major industry players worldwide and increased government funding have played a pivotal role propelling the growth of the market.

For instance, as on the data published in September 2020, by PubMed, a free search engine for biological databases and medical reports, Heart failure impacts over 64 million individuals annually on a global scale. Addressing this condition's social and economic challenges has emerged as a significant public health priority worldwide.

Furthermore, increasing the product approval given by the regulatory bodies propelling the growth of Anti-Neprilysin drug market. For instance, in February 2015, Novartis International AG a drug manufacturing company announced that the U.S. Food and Drug Administration (FDA) granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). This decision is taken to accelerate the review of therapy or medication which offers a more safety and effectiveness in the treatments, diagnosis and preventions of serious conditions.

However, cost of therapy and the substantial expenses associated with research and development and the extended timeframe needed to bring a new drug in market could potentially impede the growth of the Anti-Neprilysin drug market.

Overall, with the help of existing and modern treatment therapy the Market is expected to witness significant growth in the coming years, driven by the introduction of new therapies and an increasing demand for effective treatments.

Market- Drug Type Analysis

By Drug Type, the Anti-Neprilysin drug Market is Categories into Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others. The Sacubitril segment accounts for the largest share of around 58% of the Market in 2022.

Sacubitril dominate the market because the drug has reduced the rate of cardiovascular death and reduce the hospitalization rate related to heart failure.  Globally, the only the drug combination of sacubitril and valsartan use effectively in the treatment of heart failure patient having reduce ejection fraction, which also boost the market growth.

Market Indication Analysis

By Indication, the Anti-Neprilysin drug Market is Categories into Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others. The Acute Heart Failure segment accounts for the largest share of around 51% of the Market in 2022.

Increasing the prevalence of chronic diseases, unhealthy lifestyle habits, smoking and heavy alcohol use, lack of physical activity are factors expected to lead the highest growth Rate for this segment during the forecast period.

Moreover, Hypertension is the second segment dominate the market. Anti-Neprilysin drug drugs are a new class of drugs useful in the treatment of hypertension. The drug is effective in lowering blood pressure and can be used in people with and without heart failure. Moreover, extended research is required to determine the long-term safety and efficacy of Anti-Neprilysin drug drugs in hypertension.

Market Distribution Channel Analysis

By Distribution Channel, the Anti-Neprilysin drug Market is Categories into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital segment accounts for the largest share of around 53% of the Market in 2022.

Increasing the healthcare facilities, increasing the admission of patients, most of clinical trials initiated in hospital, convenience and easy accessibility, fuel to drive the segment. Moreover, government gives subsidies to needy or poor patients in chronic disease propel the growth of segment.

Market Regional Analysis

North America dominate the Anti-Neprilysin drug Market with the highest revenue generating market with share of more than 41%. The North America dominate this market due to the increasing technological advancements, increasing research and development in the region.

Europe having the second-largest market share in Market due to well establishes healthcare centers, increase in product developments by various organization significantly contribute to expand the market.

Asia-Pacific is estimated the fastest growing CAGR in Anti-Neprilysin drug Market in forecasted period. This is due to increasing government initiatives and policies, the increasing population rise in India and China upsurge the chronic patients leading to increase the sale in market.

Competitive Analysis

The Anti-Neprilysin drug Market is dominated by a few large companies, such as Novartis AG, BIOPROJET, Pharmaleads SA, Cipla Inc, Oceanic Pharmachem Pvt. Ltd., Theravance Biopharm

There Are Some Of The Recent Developments Of The Market:

March 2021, Stragen Pharma SA, a Switzerland-based biopharmaceutical company, started enrollment of healthy volunteers in a phase II trial of STR-324 for postoperative pain. STR-324 is an anti-nephrilysin investigational new drug (IND) candidate.

January 18, 2023, Cipla Inc., an India-based biopharmaceutical and medical company, announced the launch of Cippoint, a point-of-care testing device. The device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers.

By Drug Type

·         Sacubitril

·         TD-0714

·         STR-324

·         PL-265

·         LHW-090

·         Others

By Indication

·         Acute Heart Failure

·         Cancer Pain

·         Hypertension

·         Alzheimer’s Disease

·         Others

By Distribution Channel

·         Hospitals Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

Quality Assurance Process

1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:

• Project kickoff meeting with client
• Conduct frequent client communications
• Form project steering committee
• Assign a senior SR executive as QA Executive
• Conduct internal editorial & quality reviews of project deliverables
• Certify project staff in SR methodologies & standards
• Monitor client satisfaction
• Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.

Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.